consideration of the matters on less than seven days' notice to the public; that no earlier notice of the meeting was practicable; that the public interest did not require consideration of the matters in a meeting open to public observation; and that the matters could be considered in a closed meeting pursuant to subsections (c)(2), (c)(8), (c)(9)(A)(ii), and (c)(9)(B) of the "Government in the Sunshine Act" (5 U.S.C. 552b(c)(2), (c)(8), (c)(9)(A)(ii), and (c)(9)(B)).

Dated: March 24, 1987.

Federal Deposit Insurance Corporation.

Hoyle L. Robinson,

Executive Secretary.

[FR Doc. 87-6860 Filed 3-25-87; 11:25 am]

BILLING CODE 6714-01-M

FEDERAL DEPOSIT INSURANCE CORPORATION

Agency Meeting

Pursuant to the provisions of the "Government in the Sunshine Act" (5 U.S.C. 552b), notice is hereby given that the Federal Deposit Insurance Corporation's Board of Directors will meet in open session at 2:00 p.m. on Tuesday, March 31, 1987, to consider the following matters:

Summary Agenda: No substantive discussion of the following items is anticipated. These matters will be resolved with a single vote unless a member of the Board of Directors requests that an item be moved to the discussion agenda.

Disposition of minutes of previous meetings.

Application for Federal deposit insurance:

St. George Finance, Inc., dba St. George Thrift & Loan, an operating noninsured industrial bank located at 10 North 400 East, St. George, Utah.

Application for Federal deposit insurance and for consent to exercise full trust powers:

Yasuda Bank and Trust Company (U.S.A.), a proposed new bank to be located at One World Trade Center, Suite 8833, New York City (Manhattan), New York.

Application for consent to purchase assets and assume liabilities:

Colonial Bank, Montgomery, Alabama, an insured State member bank, for consent to purchase the assets of and assume the liabilities of First Lee County Savings and Loan Association, Opelika, Alabama, a non-FDIC-insured institution.

Application for consent to purchase assets and assume liabilities and to establish one branch:

The Central Bank, Pleasureville, Kentucky, a State nonmember bank, for consent to purchase the assets of and assume the liability to pay deposits made in the North Pleasureville Branch of Republic Savings Bank, FSB, Benton, Kentucky, a non-FDIC-insured institution, and for consent to establish that branch as a branch of The Central Bank.

Application for consent to purchase assets and assume liabilities:

Midlantic National Bank/Merchants, Neptune, New Jersey, for consent to purchase certain assets of and assume the liability to pay deposits made in three branches of Security Savings & Loan Association, Vineland, New Jersey, a non-FDIC-insured institution.

Recommendations regarding the liquidation of a bank's assets acquired by the Corporation in its capacity as receiver, liquidator, or liquidating agent of those assets:

Case No. 46,497-NR (Amendment)
Penn Square Bank, National Association, Oklahoma City, Oklahoma
Case No. 46,767-SR (Amendment)
West Coast Bank, Los Angeles (Encino), California
Case No. 46,842-L (Amendment)
United American Bank in Knoxville, Knoxville, Tennessee
Case No. 46,966-SR
Sunshine State Bank, South Miami, Florida

Reports of committees and officers:

Minutes of actions approved by the standing committees of the Corporation pursuant to authority delegated by the Board of Directors.

Reports of the Division of Bank Supervision with respect to applications; request, or actions involving administrative enforcement proceedings approved by the Director or an Associate Director of the Division of Bank Supervision and the various Regional Directors pursuant to authority delegated by the Board of Directors.

Reports of the Director, Office of Corporate Audits and Internal Investigations:

Trend Analysis Report re:
Trend Analysis of Liquidation Site Audit Results (Memo dated February 19, 1987)
Summary Audit Report re:
Continental National Bank of Kentucky, Louisville, Kentucky (2569) (Memo dated February 17, 1987)
Summary Audit Report re:
Farmers' Bank, Trimble, Tennessee (2579) (Memo dated February 13, 1987)
Summary Audit Report re:
Lubbock Consolidated Office Cost Center 403 (Memo dated February 20, 1987)
Summary Audit Report re:
LAMIS System Development Project Audit Report (Memo dated February 25, 1987)

Discussion Agenda:

Memorandum and resolution re: Proposed amendmends to Part 337 of the Corporation's rules and regulations, entitled "Unsafe or Unsound Banking Practices," which amendments, with respect to securities activities of subsidiaries of insured nonmember banks and the affiliate relationships of insured nonmember banks with securities companies, would (1) revise the existing requirement that such subsidiaries and affiliates must use separate offices from the bank that share no common entrance with the bank; (2) delete the prohibition against such subsidiaries and affiliates sharing a common name or logo with the bank; and (3) establish certain affirmative disclosure requirements to the effect that investments recommended, offered or sold by or through such subsidiary or affiliate are not FDIC-insured deposits, that the subsidiary and affiliate are separate organizations from the bank, and that the obligations of the subsidiary and affiliate are not obligations of the bank and are not guaranteed, warranted, or otherwise supported by the bank.

Memorandum and resolution re: Proposed amendments to Part 325 of the Corporation's rules and regulations, entitled "Capital Maintenance," which amendments would (1) clarify and revise certain definitions; (2) reserve the authority of the Corporation with respect to the definitions of "primary capital" and "secondary capital;" (3) specify that the terms and conditions to which capital instruments are subject must be consistent with safe and sound banking practices; and (4) limit the circumstances in which the Corporation will not approve a proposed merger transaction solely because the resulting entity does not meet the Corporation's minimum capital requirement.

Memorandum and resolution regarding a proposal relating to risk-based capital which would (1) add a risk-based capital measure (also known as a risk asset ratio) to be used in tandem with existing capital ratios, and (2) amend the definition of primary capital for purposes of computing existing capital to total assets ratios.

Memorandum re: Proposed Statement of Policy for Minimum Disclosure by Insured State Nonmember Banks which statement of policy would set forth the various types of information an insured state nonmember bank should make available to the public upon request.

The meeting will be held in the Board Room on the sixth floor of the FDIC Building located at 550—17th Street, NW., Washington, DC.

Requests for further information concerning the meeting may be directed to Mr. Hoyle L. Robinson, Executive Secretary of the Corporation, at (202) 898-3813.

Dated: March 24, 1987.

Federal Deposit Insurance Corporation.

Hoyle L. Robinson,

Executive Secretary.

[FR Doc. 87-6861 Filed 3-25-87; 11:25 am]

BILLING CODE 6714-01-M

FEDERAL DEPOSIT INSURANCE CORPORATION

Agency Meeting

Pursuant to the provisions of the "Government in the Sunshine Act" (5 U.S.C. 552b), notice is hereby given that at 2:30 p.m. on Tuesday, March 31, 1987,

the Federal Deposit Insurance Corporation's Board of Directors will meet in closed session, by vote of the Board of Directors, pursuant to sections 552(b) (c)(2), (c)(4), (c)(6), (c)(8), and (c)(9)(A)(ii) of Title 5, United States Code, to consider the following matters:

Summary Agenda: No substantive discussion of the following items is anticipated. These matters will be resolved with a single vote unless a member of the Board of Directors requests that an item be moved to the discussion agenda.

Recommendations with respect to the initiation, termination, or conduct of administrative enforcement proceedings (cease-and-desist proceeding, terminatin-of-insurance proceedings, suspension or removal proceedings, or assessment of civil money penalties) against certain insured banks or officers, directors, employees, agents or other persons participating in the conduct of the affairs thereof:

Names of persons and names and locations of banks authorized to be exempt from disclosure pursuant to the provisions of subsections (c)(6), (c)(8), and (c)(9)(A)(ii) of the "Government in the Sunshine Act" (5 U.S.C. 552b(c)(6), (c)(8), and (c)(9)(A)(ii)).

Note.—Some matters falling within this category may be placed on the discussion agenda without further public notice if it becomes likely that substantive discussion of those matters will occur at the meeting.

Memorandums regarding the Corporation's assistance agreement with an insured bank.

Discussion Agenda:

Application for Federal deposit insurance:

Brentwood Thrift and Loan Association, an operating noninsured industrial bank located at 12300 Wilshire Bouldevard, Los Angeles, California.

Personnel actions regarding appointments, promotions, administrative pay increases, reassignments, retirements, separations, removals, etc.:

Names of employees authorized to be exempt from disclosure pursuant to the provisions of subsections (c)(2) and (c)(6) of the "Government in the Sunshine Act" (5 U.S.C. 552(b) (c)(2) and (c)(6)).

The meeting will be held in the Board Room on the sixth floor of the FDIC Building located at 550—17th Street, NW., Washington, DC.

Requests for further information concerning the meeting may be directed to Mr. Hoyle L. Robinson, Executive Secretary of the Corporation, at (202) 898–3813.

Dated: March 24, 1987.

Federal Deposit Insurance Corporation.

Hoyle L. Robinson,

Executive Secretary.

[FR Doc. 87–6862 FIled 3–25–87; 11:25 am]

BILLING CODE 6714–01–M

Corrections

Federal Register
Vol. 52, No. 59
Friday, March 27, 1987

This section of the FEDERAL REGISTER contains editorial corrections of previously published Presidential, Rule, Proposed Rule, and Notice documents and volumes of the Code of Federal Regulations. These corrections are prepared by the Office of the Federal Register. Agency prepared corrections are issued as signed documents and appear in the appropriate document categories elsewhere in the issue.

DEPARTMENT OF DEFENSE
GENERAL SERVICES ADMINISTRATION
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

48 CFR Part 3

[Federal Acquisition Circular 84-24]

Federal Acquisition Regulation; Anti-Kickback Act of 1986

Correction

In rule document 87-4219 beginning on page 6120 in the issue of Friday, February 27, 1987, make the following corrections:

PART 3—[CORRECTED]

1. On page 6121, in the first column, in amendatory instruction 2, in the first line, "3.503" should read "3.502" and in the second line, "3.501-1" should read "3.502-1".

3.502-2 [Corrected]

2. On the same page, in the second column, in section 3.502-2(a), in the first line, "Prohibit" should read "Prohibits" and "persons" should read "person".

3. On the same page, in the same column, in section 3.502-2(d)(1), in the first line, "office" should read "officer".

4. On the same page, in section 3.502-2(d)(2), in the third column, in the second line, "subcontractor" should read "subcontract".

5. On the same page, in the same column, in section 3.502-2(e), in the sixth line, "is" should read "it".

6. On the same page, in the same column, in section 3.502-2(h), in the 11th line, "the audit" should read "audit the".

BILLING CODE 1505-01-D

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Housing—Federal Housing Commissioner

24 CFR Parts 200, 203, 204, 213, 220, 221, 222, 226, 227, 234, 235, 237,and 240

[Docket No. R-87-1294; FR 1928]

Single Family Mortgage Insurance on Hawaiian Home Lands

Correction

In rule document 87-5518 beginning on page 8064 in the issue of Monday, March 16, 1987, make the following corrections:

1. On page 8064, in the third column, under **Background**, in the second paragraph, in the eighth line, insert "a" between "if" and "Federal".

2. On page 8065, in the first column, in the first paragraph, in the 20th line, "of" should read "on".

3. On the same page, in the second column, in the second complete paragraph, in the fifth line, "of" should read "on".

4. On the same page, in the third column, in the first complete paragraph, in the 12th line, "if" should read "in".

5. On the same page, in the same column, in the second complete paragraph, in the fourth line, "or" should read "of".

PART 200—[CORRECTED]

6. On page 8067, in the second column, in the **Authority**, in the first line, "Title" should read "Titles".

§ 200.163 [Corrected]

7. On the same page, in the same column, in § 200.163(a)(2), in the ninth line, "mortgage" should read "mortgagor", and in the 10th line, "in" should read "is".

§ 203.439 [Corrected]

8. On page 8068, in the second column, in the 15th line from the bottom, the section number should read "203.439".

BILLING CODE 1505-01-D

federal register

Friday
March 27, 1987

Part II

Department of Health and Human Services

Food and Drug Administration

21 CFR Part 358

Wart Remover Drug Products For Over-the-Counter Human Use; Tentative Final Monograph; Notice of Proposed Rulemaking

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 358

[Docket No. 80N-0238]

Wart Remover Drug Products for Over-The-Counter Human Use; Tentative Final Monograph

AGENCY: Food and Drug Administration.

ACTION: Notice of proposed rulemaking.

SUMMARY: The Food and Drug Administration (FDA) is issuing a reproposal of the tentative final monograph (proposed rule) for over-the-counter (OTC) wart remover drug products to reflect new data and information. This reproposal is part of the ongoing review of OTC drug products conducted by FDA.

DATES: Written comments, objections, or requests for oral hearing on the proposed regulation before the Commissioner of Food and Drugs by May 26, 1987. New data relating to this notice by March 27, 1988. Comments on the new data by May 27, 1988. These dates are consistent with the time periods specified in the agency's revised procedural regulations for reviewing and classifying OTC drugs (21 CFR 330.10). Written comments on the agency's economic impact determination by July 27, 1987.

ADDRESS: Written comments, objections, or requests for oral hearing to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drugs and Biologics (HFN-210), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8000.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of October 3, 1980 (45 FR 65609), FDA published, under § 330.10(a)(6) (21 CFR 330.10(a)(6)), an advance notice of proposed rulemaking to establish a monograph for OTC wart remover drug products, together with the recommendations of the Advisory Review Panel on OTC Miscellaneous External Drug Products, which was the advisory review panel responsible for evaluating data on the active ingredients in this drug class. The agency's proposed regulation, in the form of a tentative final monograph, for OTC wart remover drug products was published in the **Federal Register** of September 3, 1982 (47 FR 39102). Interested persons were invited to file by November 2, 1982, written comments, objections, or requests for oral hearing before the Commissioner of Food and Drugs regarding the proposal.

In the **Federal Register** of January 5, 1982 (47 FR 522), FDA published, under § 330.10(a)(6) (21 CFR 330.10(a)(6)), an advanced notice of proposed rulemaking to establish a monograph for OTC corn and callus remover drug products. The agency's proposed regulation, in the form of a tentative final monograph, for OTC corn and callus remover drug products was published in the **Federal Register** of February 20, 1987 (52 FR 5412). In developing that proposal, the agency recognized that although the etiology and pathology of corns and calluses is different from that of warts, the Category I active ingredient, salicylic acid, and its mode of action, keratolysis, is common to both rulemakings.

Because no comments were submitted to the advance notice of proposed rulemaking for OTC wart remover drug products, the agency's tentative final monograph on OTC wart remover drug products proposed only minor changes from the Panel's recommendations. However, a number of comments as well as other data and information were submitted in response to the publication of the advance notice of proposed rulemaking for OTC corn and callus remover drug products. Based on that new data and information, the agency proposed a number of changes in the tentative final monograph for OTC corn and callus drug products (52 FR 5412).

Because of the similarities and overlap between the rulemakings for OTC corn and callus remover drug products and OTC wart remover drug products, the agency is proposing modifications in the tentative final monograph for OTC wart remover drug products to be consistent with the tentative final monograph for OTC corn and callus remover drug products. Because of the number of changes, the agency is restating its position on the establishment of a monograph for OTC wart remover drug products by reproposing Subpart B of Part 358 (21 CFR Part 358 Subpart B). Final agency action on this matter will occur with the publication at a future date of a final monograph, which will be a final rule establishing a monograph for OTC wart remover drug products. The definition of a wart remover drug product has been revised to be consistent with the corn/callus tentative final monograph.

A summary of the proposed changes and modifications that appear in the reproposed tentative final monograph follows:

(1) The tentative final monograph has been expanded to also include the use of a plaster vehicle containing 12 to 40 percent salicylic acid. In addition, the agency is proposing the term "collodion-like" in place of "a collodion vehicle" in describing the vehicle for liquid formulations of OTC wart remover drug products. The definition of a wart remover drug product also has been revised to be consistent with the definition of a corn and callus remover drug product, as proposed in § 358.503(a) of the tentative final monograph for OTC corn and callus remover drug products.

(2) A number of the warnings have been revised to conform with the warnings proposed in § 338.550(c) of the tentative final monograph for OTC corn and callus remover drug products.

(3) The directions for use of wart remover drug products have been revised to be similar to those proposed in § 338.550(d) of the tentative final monograph for OTC corn and callus remover drug products.

(4) Other changes have been made to conform to the format and content of other recent OTC drug tentative final monographs, e.g., the provision for other truthful and nonmisleading statements has been included in the indications section.

(5) Because of the changes summarized above, many of the paragraphs within the various sections have been redesignated.

Interested persons may communicate with the agency about the submission of data and information relating to this notice by following the procedures outlined in the agency's policy statement published in the **Federal Register** of September 29, 1981 (46 FR 47740) and clarified April 1, 1983 (48 FR 14050). That policy statement includes procedures for the submission and review of proposed protocols, agency meetings with industry or other interested persons, and agency communications on submitted test data and other information.

The agency has examined the economic consequences of this proposed rulemaking in conjunction with other rules resulting from the OTC drug review. In a notice published in the **Federal Register** of February 8, 1983 (48 FR 5806), the agency announced the availability of an assessment of these economic impacts. The assessment determined that the combined impacts of all the rules resulting from the OTC drug review do not constitute a major rule according to the criteria established by Executive Order 12291. The agency therefore concludes that not one of these rules, including this proposed rule for

OTC wart remover drug products, is a major rule.

The agency has determined that under 21 CFR 25.24(c)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Interested persons may, on or before May 26, 1987, submit to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857, written comments, objections, or requests for oral hearing before the Commissioner on the proposed regulation. A request for an oral hearing must specify points to be covered and time requested. Written comments on the agency's economic impact determination may be submitted on or before July 27, 1987. Three copies of all comments, objections, and requests are to be submitted, except that individuals may submit one copy. Comments, objections, and requests are to be identified with the docket number found in brackets in the heading of this document and may be accompanied by a supporting memorandum or brief. Comments, objections, and requests may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. Any scheduled oral hearing will be announced in the **Federal Register**.

Interested persons, on or before March 27, 1988, may also submit in writing new data relating to this notice. Written comments on the new data may be submitted on or before May 27, 1988. These dates are consistent with the time periods specified in the agency's final rule revising the procedural regulations for reviewing and classifying OTC drugs, published in the **Federal Register** of September 29, 1981 (46 FR 47730). Three copies of all data and comments on the data are to be submitted, except that individuals may submit one copy, and all data and comments are to be identified with the docket number found in brackets in the heading of this document. Data and comments should be addressed to the Dockets Management Branch (HFA–305) (address above). Received data and comments may also be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Data and comments submitted in response to the tentative final monograph for OTC wart remover drug products, published in the **Federal Register** of September 3, 1982 (47 FR 39102), have not yet been evaluated by the agency. Persons who previously submitted data and comments may wish to reevaluate them in light of this reproposed tentative final monograph.

Data and comments submitted in response to this reproposal as well as data and comments submitted in response to the tentative final monograph published in the **Federal Register** of September 3, 1982 (47 FR 39102), will be considered by the agency in establishing a final monograph. Data submitted after the closing of the administrative record on May 27, 1988, will be reviewed by the agency only after a final monograph is published in the **Federal Register**, unless the Commissioner finds good cause has been shown that warrants earlier consideration.

List of Subjects in 21 CFR Part 358

Labeling, Over-the-counter drugs, Wart remover drug products.

Therefore, under the Federal Food, Drug, and Cosmetic Act and the Administrative Procedure Act, it is proposed that Subchapter D of Chapter I of Title 21 of the Code of Federal Regulations be amended by adding Part 358 (proposed in the **Federal Register** of September 3, 1982; 47 FR 39108), Subpart B to read as follows:

PART 358—MISCELLANEOUS EXTERNAL DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

* * * * *

Subpart B—Wart Remover Drug Products

Sec.

Authority: Secs. 201(p), 502, 505, 701, 52 Stat. 1041–1042 as amended, 1050–1053 as amended, 1055–1056 as amended by 70 Stat. 919 and 72 Stat. 948 (21 U.S.C. 321(p), 352, 355, 371); 5 U.S.C. 553; 21 CFR 5.10 and 5.11.

* * * * *

Subpart B—Wart Remover Drug Products

§ 358.101 Scope.

(a) An over-the-counter wart remover drug product in a form suitable for topical application is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this subpart and each of the general conditions established in § 330.1.

(b) References in this subpart to regulatory sections of the Code of Federal Regulations are to Chapter I of Title 21 unless otherwise noted.

§ 358.103 Definitions.

As used in this subpart:

(a) *Wart remover drug product.* A topical agent used for the removal of common or plantar warts.

(b) *Collodion-like vehicle.* A solution containing pyroxylin (nitrocellulose) in an appropriate nonaqueous solvent that leaves a transparent cohesive film when applied to the skin in a thin layer.

(c) *Plaster vehicle.* A fabric, plastic, or other suitable backing material in which medication is usually incorporated for topical application to the skin.

§ 358.110 Wart remover active ingredients.

The active ingredient of the product consists of any of the following when used within the specified concentration and in the dosage form established for each ingredient:

(a) Salicylic acid 12 to 40 percent in a plaster vehicle.

(b) Salicylic acid 5 to 17 percent in a collodion-like vehicle.

§ 358.150 Labeling of wart remover drug products.

(a) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as a "wart remover."

(b) *Indications.* The labeling of the product states, under the heading "Indications," any of the phrases listed in this paragraph (b). Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph, may also be used, as provided in § 330.1(c)(2), subject to the provisions of section 502 of the act relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.

(1) "For the removal of common warts. The common wart is easily recognized by the rough 'cauliflower-like' appearance of the surface."

(2) "For the removal of plantar warts on the bottom of the foot. The plantar wart is recognized by its location only on the bottom of the foot, its tenderness, and the interruption of the footprint pattern."

(c) *Warnings.* The labeling of the product contains the following warnings under the heading "Warnings":

(1) *For products containing any ingredient identified in § 358.110.* (i) "For external use only."

(ii) "Do not use this product if you are a diabetic or have poor blood circulation, except under the advice and supervision of a doctor."

(iii) "Do not use on irritated skin or on any area that is infected or reddened."

(iv) "If discomfort persists, see your doctor."

(v) "Do not use on moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membraces."

(2) *For any product formulated in a flammable vehicle.* (i) The labeling should contain an appropriate flammability signal word, e.g., "extremely flammable," "flammable," "combustible," consistent with 16 CFR 1500.3(b)(10).

(ii) "Keep away from fire or flame."

(3) *For any product formulated in a volatile vehicle.* "Cap bottle tightly and store at room temperature away from heat."

(4) *For any product formulated in a collodion-like vehicle.* (i) "If product gets into the eye, flush with water for 15 minutes."

(ii) "Avoid inhaling vapors."

(d) *Directions.* The labeling of the product contains the following information under the heading "Directions":

(1) *For products containing salicylic acid identified in § 358.110(a).* "Wash affected area and dry thoroughly." (If appropriate: "Cut plaster to fit wart.") "Apply medicated plaster. Repeat procedure every 48 hours as needed (until wart is removed) for up to 12 weeks."

(2) *For products containing salicylic acid identified in § 358.510(b).* "Wash affected area and dry thoroughly. Apply one drop at a time to sufficiently cover each wart. Let dry. Repeat this procedure once or twice daily as needed (until wart is removed) for up to 12 weeks."

(e) The word "physician" may be substituted for the word "doctor" in any of the labeling statements in this section.

(f) The phrase "or podiatrist" may be used in addition to the word "doctor" in any of the labeling statements in this section when a product is labeled with the indication identified in § 358.150(b)(2).

Dated: February 1, 1987.

Frank E. Young,

Commissioner of Food and Drugs.

[FR Doc. 87-6703 Filed 3-26-87; 8:45 am]

BILLING CODE 4160-01-M